Cidara Shares Rally Premarket as J&J Moves Forward on Influenza Pact
By Colin Kellaher
Shares of Cidara Therapeutics rose sharply in premarket trading Wednesday after the biotechnology company said a Johnson & Johnson unit plans to proceed with the development of CD388 for the prevention of influenza A and B.
San Diego biotechnology company Cidara said it will receive a $7 million milestone payment from J&J's Janssen unit, which will assume responsibility for future development, manufacturing and commercialization activities of CD388.
Cidara, which had signed an influenza license and collaboration agreement with Janssen in 2021, said it is eligible to receive up to an additional $685 million in milestone payments under the deal, along with royalties on product sales.
Cidara shares, which closed Tuesday at 79.3 cents, were recently up 11% at 88 cents in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 06, 2023 08:53 ET (12:53 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom